IL-2 Variant Engineering for Selective Treg Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-2 therapies face challenges such as high toxicity at high doses, short half-life, and limited efficacy in cancer treatment, along with Tregs-mediated immunosuppression, necessitating improved IL-2 variants for selective stimulation or antagonism of Tregs to enhance immune responses.
Innovation Solution
Engineering human IL-2 variants with specific amino acid substitutions and deletions to preferentially stimulate or inhibit Tregs, including H16R, L19R, and V91K mutations, to modulate IL-2 signaling for targeted immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of IL-2 are administered to stimulate immune response against cancer, then immune activation is enhanced, but toxicity increases and efficacy is limited due to unwanted effects on Tregs
Solution Approach 1:
The patent applies local quality by creating IL-2 variants with specific amino acid substitutions (H16R, L19R, V91K) that selectively alter binding affinity to different IL-2R subtypes. These variants are designed to preferentially interact with CD122+ cells (effector T cells and NK cells) while having reduced activity on CD25+ Tregs, thereby achieving localized immunomodulation effects in different cell populations
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequence of IL-2 to create variants with altered biological properties. The specific substitutions (H16R, L19R, V91K) change the molecular parameters of IL-2, resulting in variants with extended half-life and modified receptor binding characteristics that enhance efficacy while reducing toxicity
2Reliability
If low doses of IL-2 are administered to boost Tregs and dampen inflammation, then immunosuppression is achieved, but half-life is very short requiring repeated administration
Solution Approach 1:
The patent applies parameter changes by introducing amino acid substitutions that fundamentally alter the pharmacokinetic parameters of IL-2. The variants exhibit extended half-life through modified protein stability and reduced clearance rates, allowing sustained immunosuppressive activity at low doses without requiring frequent re-administration
3Reliability
If IL-2 is complexed with anti-IL-2 antibody to improve pharmacodynamics and reduce toxicity, then Treg selectivity is enhanced, but treatment complexity increases
Solution Approach 1:
The patent applies the taking out principle by extracting the Treg-selectivity function from the complex IL-2/anti-IL-2 antibody system and incorporating it directly into the IL-2 molecule itself through amino acid substitutions. This eliminates the need for separate antibody components while maintaining the desired selective Treg modulation effect
Solution Approach 2:
The patent merges multiple functions into a single IL-2 variant molecule. The variant simultaneously provides Treg selectivity, extended half-life, and appropriate effector cell activity all within one protein entity, simplifying the treatment approach compared to using separate IL-2 and antibody components
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~3C
AI summary
The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.